Search results for "Organo"

showing 10 items of 1460 documents

Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.

2014

In hepatitis B e antigen (HBeAg) positive-HIV co-infected patients treated with combined antiretroviral therapy (cART), including tenofovir disoproxil fumarate (TDF), the rate of HBe seroconversion remains low. Whether adding pegylated interferon alfa (PegIFN) could increase the likelihood of HBeAg loss and HBe seroconversion has not been assessed.A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months. The primary endpoint was HBV sustained response: HBe seroconversion with undetectable HBV DNA levels 24 weeks after completing PegIFN therapy (W72).Fifty-one patients (49 men, median age 46 years, range: 32-6…

AdultMalemedicine.medical_specialtyHBsAgOrganophosphonatesHIV Infectionsmedicine.disease_causeEmtricitabineGastroenterologyAntiviral AgentsDeoxycytidinePolyethylene GlycolsHepatitis B ChronicPegylated interferonInternal medicineAntiretroviral Therapy Highly ActivemedicineEmtricitabineHumansHepatitis B e AntigensSeroconversionTenofovirHepatitis B virusDrug CarriersHepatologybusiness.industryCoinfectionAdeninevirus diseasesLamivudineHIVInterferon-alphaMiddle AgedViral Loaddigestive system diseasesRecombinant ProteinsCD4 Lymphocyte CountTreatment OutcomeHBeAgLamivudineImmunologyFemalebusinessViral loadmedicine.drugJournal of hepatology
researchProduct

MR angiography of the pedal arteries with gadobenate dimeglumine, a contrast agent with increased relaxivity, and comparison with selective intraarte…

2007

Purpose To compare gadobenate dimeglumine (Gd-BOPTA)–enhanced MR angiography (i.e., contrast-enhanced MRA [CE-MRA]) of the pedal vasculature with selective digital subtraction angiography (DSA) in patients with peripheral arterial occlusive disease (PAOD). Materials and Methods A total of 22 patients with PAOD were prospectively examined at 1.5T. For contrast enhancement, 0.1 mmol/kg body weight of Gd-BOPTA were applied. MRA consisted of dynamic imaging with acquisition of six consecutive data sets. Acquisition time for each data set was 24 seconds, voxel size was 1.0 × 1.0 × 1.3 mm3. A total of 20 out of 22 patient underwent selective DSA, two patients fine-needle DSA. DSA and MRA were per…

AdultMalemedicine.medical_specialtyImage qualitymedia_common.quotation_subjectDynamic imagingContrast MediaArterial Occlusive DiseasesMegluminemedicineOrganometallic CompoundsContrast (vision)HumansRadiology Nuclear Medicine and imagingIn patientcardiovascular diseasesProspective StudiesGADOBENATE DIMEGLUMINEVascular Patencymedia_commonAgedAged 80 and overPeripheral Vascular Diseasesmedicine.diagnostic_testbusiness.industryFootMr angiographyAngiography Digital SubtractionDigital subtraction angiographyMiddle Agedmedicine.diseasebody regionsStenosiscardiovascular systemFemaleRadiologyNuclear medicinebusinessMagnetic Resonance Angiographycirculatory and respiratory physiologyJournal of magnetic resonance imaging : JMRI
researchProduct

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter R…

2020

BACKGROUND Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). OBJECTIVE The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC. METHODS This is a French multicenter randomized phase II trial in patients with resectable high-risk T3, T4, and/or N2 CC on baseline computed tomography (CT) scan. Patients were randomized to receive either 6 months of adjuvant FOLFOX after colectomy (control) or perioperative FOLFOX for 4 cycles before surgery and 8 cycles after (FOLFOX peri-op). In RAS wild-type patients, a third arm testing perioperative FOLFOX-cetuximab was added…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinCetuximab03 medical and health sciences0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsMedicineHumanseducationColectomyColectomyAgedNeoplasm StagingTumor Regression Gradeeducation.field_of_studybusiness.industryPerioperativeMiddle Agedmedicine.diseaseInterim analysisdigestive system diseasesNeoadjuvant Therapy3. Good healthSurgeryTolerability030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologySurgeryFemaleFluorouracilFrancebusinessTomography X-Ray Computedmedicine.drugAnnals of surgery
researchProduct

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

2005

Purpose: To verify the experience of the GOIM in the treatment of advanced colorectal cancer patients with the FOLFIRI combination therapy. Patients and methods: Patients entered in three consecutive trials of the GOIM (protocols no. 9706, 9901, and 2301) were reported in this analysis. A total of 287 chemotherapy-naive patients were treated with FOLFIRI regimen: Irinotecan 180mg/m 2 on day 1 with LV5FU2 regimen (LV at 100mg/m 2 administered as a 2-hour infusion before FU at 400mg/m 2 as an intravenous bolus injection, and FU at 600mg/m 2 as a 22-hour infusion immediately after 5FU bolus injection on day 1 and 2); the treatment was repeated every 2 weeks. Results: 287 patients entered in th…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsCombination therapyColorectal cancerLeucovorinGastroenterologyFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsFOLFIRI RegimenHumansMedicineAgedSulfonamidesbusiness.industryCarcinomaLiver NeoplasmsHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanRegimenTreatment OutcomeOncologyCelecoxibFluorouracilFOLFIRIPyrazolesCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

2006

Background The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer. Patients and methods Eighty-one chemotherapy-naive patients entered in this randomized phase II trial of the GOIM (protocol no. 2301). Patients were randomized to receive FOLFIRI regimen (arm A): irinotecan 180 mg/m2 on day 1 with LV5FU2 regimen (LV at 100 mg/m2 administered as a 2-h infusion before FU at 400 mg/m2 as an intravenous bolus injection, and FU at 600 mg/m2 as a 22-h infusion immediately after 5-FU bolus injection on day 1 and 2); or FOLFIRI plus celecoxib 400 mg twice daily for 14 days (arm B). Both…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsLeucovorinPhases of clinical researchIrinotecanGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsFOLFIRI RegimenHumansMedicineAgedSulfonamidesbusiness.industryHematologyMiddle AgedSurgeryOxaliplatinIrinotecanRegimenTreatment OutcomeOncologyCelecoxibFluorouracilCelecoxibFOLFIRIPyrazolesCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safet…

2007

Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support. Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity. Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) …

AdultMalemedicine.medical_specialtyPancreatic diseaseOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinAdenocarcinomaInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedRetrospective StudiesChemotherapyPerformance statusbusiness.industryCancerHematologyMiddle Agedmedicine.diseaseChemotherapy regimenGemcitabineDrug Resistance MultipleSurgeryPancreatic NeoplasmsFOLFOX4 regimen pancreatic carcinoma second-line chemotherapyRegimenOncologyChemotherapy AdjuvantDrug Resistance NeoplasmFemaleFluorouracilbusinessmedicine.drug
researchProduct

Assessment of atrial diastolic function in patients with hypertrophic cardiomyopathy by cine magnetic resonance imaging

2015

Purpose: This study was conducted to assess the role of atrial function by cardiac magnetic resonance (CMR) for the evaluation of diastolic physiology in patients with hypertrophic cardiomyopathy (HCM) compared to healthy controls. Materials and methods: We enrolled 23 consecutive patients affected by HCM and 43 healthy subjects as age-matched control cases (CC). CMR was performed through acquisition of cine steady-state free precession sequences using a 1.5-T scanner. Image postprocessing was carried out using Tracking Tool software. Results: Atrial volumes were significantly higher in patients with HCM compared to CC: maximum atrial volume (p = 0.007) and minimum atrial volume (p = 0.01).…

AdultMalemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingDiastolic functionCardiac magnetic resonanceDiastoleContrast MediaMagnetic Resonance Imaging CineDiastoleInternal medicineImage Interpretation Computer-AssistedmedicineOrganometallic CompoundsHumansIn patientDiastolic functioncardiovascular diseasesHeart AtriaNeuroradiologyOrganometallic Compoundmedicine.diagnostic_testbusiness.industryMedicine (all)UltrasoundAtrial functionHypertrophic cardiomyopathyMagnetic resonance imagingInterventional radiologyGeneral MedicineCardiomyopathy Hypertrophicmedicine.diseaseHypertrophic cardiomyopathyCase-Control Studiescardiovascular systemCardiologyFemalebusinessCase-Control StudieSettore MED/36 - Diagnostica Per Immagini E RadioterapiaHuman
researchProduct

Imaging findings of hepatic focal nodular hyperplasia in men and women: are they really different?

2014

Purpose This study was undertaken to compare the imaging findings of focal nodular hyperplasia (FNH) in men and women, as seen on multidetector computed tomography (MDCT), magnetic resonance imaging (MRI) and contrast-enhanced ultrasound (CEUS). Materials and methods Two radiologists reviewed 195 imaging studies (17 MDCT, 81 MRI and 97 CEUS examinations) pertaining to 111 FNHs (mean size 3 cm) in 91 patients (mean age 39 years). For each lesion, the readers assessed size, location, echogenicity, attenuation, or signal intensity in comparison with adjacent liver parenchyma on both unenhanced and postcontrast images. Results Eighty-nine FNHs (mean size 3.1 cm) were observed in 73 women (mean …

AdultMalemedicine.medical_specialtySulfur HexafluorideContrast MediaSettore MED/01 - Statistica MedicaMeglumineSex FactorsSex factorsMultidetector computed tomographyMultidetector Computed TomographyOrganometallic CompoundsMedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesPhospholipidsNeuroradiologyAgedmedicine.diagnostic_testbusiness.industryUltrasoundFocal nodular hyperplasiaMagnetic resonance imagingInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingFocal nodular hyperplasia liver Computed tomographyMagnetic resonance imagingContrast-enhanced ultrasoundIopamidolFocal Nodular Hyperplasiacardiovascular systemFemaleRadiologybusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaContrast-enhanced ultrasound
researchProduct

The importance of citrates in treatment and prophylaxis of calcium oxalate urinary stones

2017

About 10% of the people is the subject of an episode of kidney stones during their lifetime, about 70% of these people undergoes relapses. About 80% of the urinary stones contains calcium, of wich 80% is formed of calcium oxalate, in pure form or associated with calcium phosphate. Therefore we can saythat in most cases (about 65%) the urinary stones are composedof calcium oxalate. Use of supplements of potassium citrate and magnesium citrate can help in the prevention of kidney stones of calcium oxalate, but mostly they can be used in the days before a shockwaves lithotripsy treatment to make the stones more fragile to the effect of the shock waves. A case of successful treatment with magne…

AdultMalemedicine.medical_specialtyUreteral CalculiUrologymedicine.medical_treatmentUrinary systemPotassiumUrologyCalcium oxalatechemistry.chemical_elementLithotripsyCalciumlcsh:RC870-923Citric Acidchemistry.chemical_compoundPotassium CitrateOrganometallic CompoundsmedicineHumansCalcium OxalateMagnesiumbusiness.industryCalcium oxalate stones prophylaxislcsh:Diseases of the genitourinary system. Urologymedicine.diseaseSurgerychemistryKidney stonesbusinessCitric acidArchivio Italiano di Urologia e Andrologia
researchProduct